GSK's ECLIPSE study links improved health status to reduced COPD morbidity and mortality

New findings from the GSK-sponsored ECLIPSE study, published in the journal Thorax, indicate that patients with chronic obstructive pulmonary disease (COPD) who experience an improving or stable health status show significantly reduced rates of exacerbations, hospital admissions, and mortality.

The analysis, which included 1,832 patients with at least 12 months of follow-up, found that those with an improved or stable health status, as measured by the St George's Respiratory Questionnaire (SGRQ), experienced fewer COPD exacerbations and hospitalizations compared to patients whose health status deteriorated. The study also revealed a lower mortality risk in patients with improved or stable SGRQ scores. These results align with recommendations from the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) to consider health status improvement as a key management objective.

John W. Walsh, Co-founder and President of the COPD Foundation, commented on the significance of the data, noting its importance given that approximately half of all COPD patients suffer exacerbations with substantial impacts on their well-being. He encouraged patients to collaborate with their physicians to leverage tools like the COPD Assessment Test for more effective disease management.

Professor Emiel F.M Wouters of Maastricht UMC+ stated that the findings suggest that actively managing or improving a patient's health status, even over a one-year period, can positively affect morbidity and mortality. He expressed hope that these results will motivate healthcare professionals to closely monitor COPD patients' health status, enabling early identification and intervention for declining patients to potentially improve outcomes.